| Title |
Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence
|
|---|---|
| Published in |
Current Urology Reports, September 2017
|
| DOI | 10.1007/s11934-017-0736-1 |
| Pubmed ID | |
| Authors |
Jason Bailey, Morand Piert |
| Abstract |
Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC ((68)Ga-PSMA) have shown promise for unmet diagnostic needs in prostate cancer. (68)Ga-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary disease, (68)Ga-PSMA appears to preferentially identify treatment-relevant intermediate and high-risk prostate cancer. There is also a growing evidence that (68)Ga-PSMA positron emission tomography (PET) outperforms alternative conventional imaging methods including choline-based radiotracers for the localization of disease sites at biochemical recurrence, particularly at lower prostate-specific antigen (PSA) levels (< 1 ng/mL). However, the majority of published work lacks rigorous verification of imaging results. (68)Ga-PSMA offers significant promise for both, primary disease and biochemically recurrent prostate cancer. The evidence base to support (68)Ga-PSMA is however still underdeveloped, and more rigorous studies substantiating efficacy are needed. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Colombia | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 21% |
| Other | 7 | 11% |
| Student > Postgraduate | 7 | 11% |
| Student > Master | 6 | 10% |
| Student > Ph. D. Student | 4 | 6% |
| Other | 6 | 10% |
| Unknown | 19 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 48% |
| Chemistry | 2 | 3% |
| Computer Science | 2 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Nursing and Health Professions | 1 | 2% |
| Other | 7 | 11% |
| Unknown | 19 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2017.
All research outputs
#15,167,432
of 23,327,904 outputs
Outputs from Current Urology Reports
#460
of 602 outputs
Outputs of similar age
#188,459
of 316,999 outputs
Outputs of similar age from Current Urology Reports
#9
of 13 outputs
Altmetric has tracked 23,327,904 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 602 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,999 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.